RedETSA Convenes 38 HTA Institutions for Americas Summit
Regional HTA network addresses equity, economic evaluation, and adaptation frameworks.
Read MorePosted by Shajini | Jun 9, 2025 | News, Pricing & Market Access
Regional HTA network addresses equity, economic evaluation, and adaptation frameworks.
Read MorePosted by Shajini | Jun 9, 2025 | News, Pricing & Market Access
Platform achieves 30% market dominance in Medicare Advantage bid submissions.
Read MorePosted by Shajini | Jun 9, 2025 | Monthly Insight's
Top biopharma deals, FDA approvals, and market access news from the past week.
Read MoreChina’s National Medical Products Administration has granted a second Breakthrough Therapy Designation to Innovent Biologics’ IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating...
Read MorePosted by Shajini | Jun 6, 2025 | News, Pricing & Market Access
The National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million...
Read More